Rossi Dino A received 1,658 derivative securities of Krystal Biotech, Inc. across two transactions dated September 14, 2026, with each recorded at $0 per share. The transaction code identifies the entries as awards, allowing investors to distinguish them from open-market purchases, sales or other insider activity.
Key Highlights
- The two transactions were dated September 14, 2026.
- Each transaction carried a recorded price of $0 per share.
- Both entries used SEC transaction code A, which denotes an award or grant.
The securities were issued across two separate transactions. The transactions were dated September 14, 2026, and each was recorded at $0 per share. Krystal Biotech, Inc. is identified in the transaction record as KRYS. It distinguishes the 1,658 securities from transactions coded as open-market purchases or sales. The $0 per-share entry reflects the recorded transaction price for the awards. The activity involved derivative securities rather than common stock.
FAQs
Q: What did Rossi Dino A receive from Krystal Biotech?
A: Rossi Dino A received 1,658 derivative securities of Krystal Biotech, Inc. The securities were issued through two separate transactions dated September 14, 2026.
Q: Were Rossi Dino A’s Krystal Biotech securities bought on the market?
A: No. The 1,658 securities were derivative securities rather than common stock, and the transaction record distinguishes them from open-market purchases or sales.
Q: When were Rossi Dino A’s transactions recorded?
A: The two Krystal Biotech derivative-security transactions were dated September 14, 2026. Both transactions involved awards recorded at $0 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.